

Dear Fellow Medicinal Chemists,

*Annual Reports in Medicinal Chemistry* continues to be the key publication in our field for over forty years. Volume 44 should be delivered in early December for your reading pleasure and reference.

The chapters in Volume 44 have been completed and are now being processed for the book. The Table-of-Contents is included as an attachment (PDF) in this e-mail. I am now starting to think about Volume 45 (to be published in November, 2010). **I am writing you to solicit reviews appropriate for *Annual Reports in Medicinal Chemistry*.** Listed below are the Section Editors for Volume 45. If you feel that you want to contribute a review for the book, please contact the appropriate Section Editor. All reviews are approximately 10-15 pages in length (approximately 5000 words), and Section Editors are responsible for the content of their sections. The first step in proposing a chapter is sending the appropriate Section Editor a one-page outline of the review, including a list of co-authors and contact information. This is due by October 31<sup>st</sup>, 2009, but should be sent as soon as possible for review by the Section Editor. *We are especially interested in case histories that highlight the non-linear path to making a drug, as these stories are the most instructive for your fellow medicinal chemists.*

**This solicitation to the general Medicinal Chemistry community is our attempt to make sure that we get the best reviews possible for Volume 45, and to make sure that the process of selection is completely open to the entire Medicinal Chemistry community.** Please consider contributing and contacting a Section Editor with a review theme. I would like to thank all involved with Volume 44 in advance, and am looking forward to making it a useful resource for the Medicinal Chemistry community again.

Please also note that I am also actively soliciting feedback from the Medicinal Chemistry community as to how you might want *Annual Reports in Medicinal Chemistry* to change and evolve. Please feel free to e-mail me [john.macor@bms.com] with your thoughts and suggestions. While this request has been sent in different forms on different occasions, to date, I have received only a few replies.

Sincerely,

John Macor, PhD  
Editor-in-Chief, *Annual Reports in Medicinal Chemistry* (Volumes 42-46)  
john.macor@bms.com

#### **Section Editors – Volume 45 - *Annual Reports in Medicinal Chemistry***

##### **Central Nervous System Diseases**

Albert J. Robichaud E-mail: robicha@wyeth.com

##### **Cardiovascular & Metabolic Diseases**

Andy Stamford E-mail: andrew.stamford@spcorp.com

##### **Inflammatory, Pulmonary & Gastrointestinal Diseases**

Joel Barrish E-mail: joel.barrish@bms.com

##### **Oncology**

Shelli McAlpine E-mail: mcalpine@sciences.sdsu.edu

##### **Infectious Diseases**

John Primeau E-mail: john.primeau@astrazeneca.com

##### **Topics in Biology**

John Lowe E-mail: john.a.lowe@pfizer.com

##### **Topics in Drug Design & Discovery**

Manoj C. Desai E-mail: manoj.desai@gilead.com

**Summary Sheet ARMC - Volume 44 - 2009**

<b>LIST OF CHAPTERS AND AUTHORS - A.R.M.C. - Volume 44 (To be Published in 2009)</b>			
<b>#</b>	<b>TITLE</b>	<b>AUTHOR(S)</b>	<b>AUTHOR e-Mail Address</b>
<b>I. Central Nervous System Diseases - ROBICHAUD</b>			
1	Recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer's disease	Robert G. Gentles, Shuanghua Hu, and Gene Dubowchik.	robert.gentles@bms.com
2	Advances in the Development of Nitric Oxide Synthase Inhibitors	Shawn Maddaford, Subhash Annendi, Jailall Remnauth, and Suman Rakhit	smaddaford@neuraxon.com
3	Small Molecule Protein-Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Current Progress and Future Hurdles	Simon Haydar and Warren Hirst	haydars@wyeth.com
4	Case History: Chantix (varenicline tartrate) a Nicotinic Partial Agonist Aid to Smoking Cessation	Jotham W. Coe, Hans Rollema and Brian T. O'Neill	jotham.w.coe@pfizer.com
<b>II. Cardiovascular and Metabolic Diseases - STAMFORD</b>			
5	Case History on Tekturna® /Rasilez® (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension	Juergen Maibaum and David Feldman (Novartis)	juergen_klaus.maibaum@novartis.com
6	Advances in Vasopressin Receptor Agonists and Antagonists	Thomas Ryckmans (Pfizer)	Thomas.Ryckmans@pfizer.com
7	The Emergence of GPR119 Agonists as Anti-diabetic Agents	Robert Jones (Arena Pharmaceuticals)	RJones@arenapharm.com
8	Non-peptide Ligands for the Gonadotropin Receptors	Nicole van Straten, Marco Timmers (Schering-Plough)	nicole.vanstraten@spcorp.com
9	Recent Advances in Coagulation Serine Protease Inhibitors	Mimi Quan and Joanne Smallheer, Bristol-Myers Squibb	mimi.quan@bms.com
<b>III. Inflammation / Pulmonary / GI - BARRISH</b>			
10	Advances in the Discovery of Anti-Inflammatory FMS Inhibitors	Mark Player and Carl Manthey (J&J)	MPLAYER@its.jnj.com
11	Recent Advances in the Discovery of CB2 Selective Agonists	Jayant Thatte, Sangdon Han, and Rob Jones (Arena)	JThatte@arenapharm.com
12	Advances in the Discovery of Small Molecule JAK3 Inhibitors	Stephen Wroblewski (BMS)	stephen.wroblewski@bms.com
13	Recent Advances in Adenosine Receptor (AR) Ligands in Pulmonary Diseases	Jeff Zablocki and Rao Kalla (CV Therapeutics)	Jeff.Zablocki@cvt.com
<b>IV. Oncology - MYLES</b>			
14	Recent Progress in the Development of Small Molecule Inhibitors of Insulin-like Growth Factor Receptor (IGF-1R) Kinase	Dinesh Vyas and Mark Wittman	mark.wittman@bms.com
15	Case History: Discovery of Ixabepilone (IXEMPRA™), a First-in-class Etoposide Analogue for Treatment of Metastatic Breast Cancer	Robert M. Borzilleri and Gregory D. Vite	robert.borzilleri@bms.com
16	Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics	Stefan Peuker and Karen Miller-Moslin	stefan.peukert@novartis.com
17	Emerging Therapies Based on Inhibitors of Phosphatidylinositol-3-Kinases (PI3Ks)	John M. Nuss, Amy Lew Tsuhako and Neel K. Anand Exelixis, Inc.	jnuss@exelixis.com
<b>V. Infectious Diseases - Primeau</b>			
18	Anti-infective Activity of Artemisinin and its Semi-synthetic Derivatives	John G. D'Angelo (Alfred Univ.)	dangelo@alfred.edu
19	Recent Advances in the Inhibition of Bacterial Type II Topoisomerases	Greg Bisacchi & Jacques Dumas (AstraZeneca)	greg.bisacchi@astrazeneca.com
20	Progress Towards the Discovery and Development of Specifically Targeted Inhibitors of Hepatitis C Virus	Nicholas A. Meanwell John F. Kadow and Paul M. Scol	nicholas.meanwell@bms.com
<b>VI. Topics in Biology - LOWE</b>			
21	Inhibitors of Nuclear Hormone Receptor/Steroid Receptor Coactivator Interactions	Terry Moore, John Katzenellenbogen	twm96a@yahoo.com
22	Safety Testing of Drug Metabolites	Tom Thompson	tnt@rdservkc.com
23	A Path to Innovation: Gene Knockouts Model New Drug Action	Brian Zambrowicz	brian@lexpharma.com
<b>VII. Topics in Drug Design and Discovery - DESAI</b>			
24	Discovery of Novel Positron Emission Tomography (PET) Tracers	Dennis McCarthy	dennis.mccarthy@astrazeneca.com
25	The Use of Isotopically Labeled Compounds in Drug Discovery	(Chad) Charles S. Elmore	chad.elmore@astrazeneca.com
26	Mechanism based inhibition of CYP3A4 and other cytochromes P450	Bernard Murray	bernard.murray@gilead.com
27	Nonclinical Toxicogenomics in the Pharmaceutical Environment	Bruce D. Car	bruce.car@bms.com
<b>VIII. Trends and Perspectives</b>			
28	To Market, To Market 2008	Shridhar Hegde and Michelle Schmidt	michelle.a.schmidt@pfizer.com